with a single Phe508del allele. N Engl J Med 381, 1809-1819( 2019).
36. Shaughnessy, C. A., Zeitlin, P. L. & Bratcher, P. E. Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment. Sci Rep 11, 19810( 2021).
37. Condren, M. E. & Bradshaw, M. D. Ivacaftor: a novel gene-based therapeutic approach for cystic fibrosis. J Pediatr Pharmacol Ther 18, 8-13( 2013).
38. Guo, J., Wang, J., Zhang, J., Fortunak, J. & Hill, A. Current prices versus minimum costs of production for CFTR modulators. Journal of Cystic Fibrosis 21, 866-872( 2022).
39. West Virginia.( United States Census Bureau).
40. Elexacaftor, tezacaftor, and ivacaftor co-packaged with ivacaftor: Drug information. Vol. 2024( UpToDate).
41. Lomunova, M. A. & Gershovich, P. M. Gene therapy for cystic fibrosis: Recent advances and future prospects. Acta Naturae 15, 20-31( 2023).
42. Huang, W., Smith, A. T., Korotun, M., Iacono, A. & Wang, J. Lung transplantation in a new era in the field of cystic fibrosis. Life( Basel) 13( 2023).
43. Ramos, K. J., et al. Lung transplant referral for individuals with cystic fibrosis: Cystic fibrosis foundation consensus guidelines. J Cyst Fibros 18, 321-333( 2019).
44. Bower, J. K., et al. WS01.04 Real-world outcomes in people with cystic fibrosis( pwCF) treated with elexacaftor / tezacaftor / ivacaftor( ELX / TEZ / IVA) with up to three years of follow-up. Journal of Cystic Fibrosis 23, S2( 2024).
45. Benninger, L. A., Trillo, C. & Lascano, J. CFTR modulator use in post lung transplant recipients. J Heart Lung Transplant 40, 1498-1501( 2021).
46. Mudigonda, G. R., Holladay, R. & Charoenpong, P. Disparities in the prelung transplantation process for rural patients at a nontransplantation center. Chest 165, 178-180( 2024).
47. Sontag, M. K., et al. Newborn Screening for Cystic Fibrosis: A qualitative study of successes and challenges from universal screening in the United States. Int J Neonatal Screen 8( 2022).
Protect What Matters Most
Let Deacon & Deacon help ensure a secure future for your family and business with custom solutions for:
Employer Group Medical Plans with unique cost containment solutions and proven performance
Life Insurance for family and business needs
Disability Income Insurance to protect your greatest asset- your ability to provide
Long-Term Care Insurance to protect against the largest risk to your retirement and estate
Annuities provide tax deferral, growth with guarantees or market index participation
( 304) 720-5641 | joseph @ deaconanddeacon. com | deaconanddeacon. com 1210 Kanawha Boulevard East, Charleston, WV 25301 insurance & benefits CONSULTING
18 • www. wvsma. org